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Summary
Bendamustine in combination with rituximab (BR) has been associated with high response rates 
and acceptable toxicity in older patients with relapsed/refractory diffuse large B-cell lymphoma 
(DLBCL). Evaluation of BR is warranted in the front-line setting for DLBCL patients not eligible 
for anthracyclines or for the elderly. In this phase II study, we enrolled DLBCL patients aged ≥65 
years who were poor candidates for R-CHOP (rituximab, cyclophosphamide, doxorubicin, 
vincristine, prednisone) to determine the efficacy and safety of BR in previously untreated stage 
II–IV DLBCL. Twenty-three patients were enrolled with a median age of 80 years. 52% of 
patients presented with poor functional status (Eastern Cooperative Oncology Group performance 
score of ≥2). The overall response rate was 78% with 12 complete responses (52%). At a median 
follow up of 29 months, the median overall survival was 10.2 months and the median progression-
free survival was 5.4 months. The most common grade 3/4 adverse events were haematological. 
Combination therapy with BR demonstrates high response rates as front-line therapy in frail older 
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patients with DLBCL, but survival rates were low. BR should be used with caution in future 
clinical trials involving older DLBCL patients with poor functional status.
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Introduction
Non-Hodgkin lymphoma (NHL) is the seventh most common type of cancer with over 
70,000 new cases of NHL diagnosed annually in the United States (Siegel, et al 2015). 
Diffuse large B-cell lymphoma (DLBCL), an aggressive sub-type of lymphoma, is the most 
common type of NHL and is a disease of the elderly, with a median age of 70 years at 
diagnosis (Smith, et al 2011). A major advance in the therapy of NHL has been the 
development of monoclonal antibodies, such as rituximab, a chimeric anti-CD20 antibody. 
Chemo-immunotherapy with R-CHOP [rituximab combined with CHOP 
(cyclophosphamide, doxorubicin, vincristine, prednisone)] has been shown to be more 
effective in the treatment of elderly patients with DLBCL than CHOP alone, without added 
toxicity (Coiffier, et al 2002, Feugier, et al 2005, Habermann, et al 2006), with one study 
showing a complete response (CR) rate of 75% and a 5-year progression-free survival (PFS) 
of 54% in patients receiving R-CHOP (Coiffier, et al 2002, Feugier, et al 2005). However, 
there were still a significant number of patients with severe adverse events in these studies 
including a treatment-associated death rate of up to 14% (Feugier, et al 2005). Given this 
level of toxicity associated with R-CHOP, even in a selected group of older DLBCL patients 
with good baseline performance status, novel therapeutic strategies are urgently needed to 
improve survival outcomes, especially in older patients who may not tolerate aggressive 
chemotherapy, such as R-CHOP.
Bendamustine is an alkylating agent with properties of a purine analogue and is approved by 
the U.S. Food and Drug Administration (FDA) for treatment of chronic lymphocytic 
leukaemia (CLL) and indolent NHL. The success of bendamustine combined with rituximab 
(BR) in indolent NHL (Robinson, et al 2008, Rummel, et al 2013) generated interest in the 
study of this combination in aggressive NHL. A phase 1 study of BR in patients with 
relapsed or refractory aggressive B-cell NHL found a maximum tolerated dose of 120 
mg/m2 on a 21-day cycle and showed the combination to be well tolerated with promising 
efficacy (Ogura, et al 2011). Several phase II studies of BR in patients with relapsed or 
refractory DLBCL who were not eligible for autologous stem cell transplant showed 
promising efficacy with overall good tolerance of this regimen in the salvage setting 
(Ohmachi, et al 2013, Vacirca, et al 2014).
Based on the promising clinical data summarized above, we conducted a phase II trial using 
bendamustine 90 to 120 mg/m2/day on days 1 and 2, depending on Eastern Cooperative 
Oncology Group (ECOG) performance status (PS), in combination with rituximab 375 
mg/m2 on day 1 every 21 days for treatment of older patients (aged ≥ 65 years) with 
previously untreated stages II–IV DLBCL who were deemed to be poor candidates for R-
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CHOP. The purpose of this study was to determine whether BR is a safe, feasible and 
effective treatment option for these patients. In addition, we conducted a geriatric 
assessment (Hurria, et al 2005) at baseline to further investigate other factors associated with 
toxicity and outcome in older DLBCL patients treated with chemotherapy.
Methods
Study Design and Objectives
This single arm phase II trial was designed to investigate the efficacy and safety of BR in 
previously untreated older patients with stage II–IV DLBCL (ClinicalTrials.gov 
NCT01234467). The primary end point was CR rate. Secondary end points were overall 
response rate (ORR), disease-free survival (DFS), PFS and overall survival (OS) at 3 years, 
toxicity and tolerability, and geriatric assessment (GA) at baseline.
Patient Eligibility
Patients aged 65 years or older with ECOG PS 0–3 and previously untreated histologically 
confirmed CD20+ DLBCL were eligible for the study. Patients were required to have 
measurable disease, either by lesions that could be accurately measured in 2 dimensions by 
computerized tomography with a greatest transverse diameter of 1 cm or greater or by bone 
marrow histopathology. Patients were required to be deemed a poor candidate for R-CHOP 
due to ejection fraction ≤45%, ECOG PS ≥ 2, or based on the treating physician’s discretion. 
Baseline laboratory parameters included haemoglobin >80 g/l, absolute neutrophil count 
(ANC) >1.0 cells × 109/l, platelet count > 75 × 109/l and adequate hepatic and renal 
function, demonstrated by aspartate aminotransferase (AST) < 2.5 x upper limit normal 
(ULN), total serum bilirubin < 2.5 x ULN, and serum creatinine < 1.5 x ULN. Patients with 
a history of hepatitis or with central nervous system involvement by lymphoma were 
excluded from the study. Patients from several different community sites across the state 
were included in this protocol through the University of North Carolina Cancer Network. All 
patients signed an institutional review board (IRB)-approved informed consent document for 
this protocol.
Treatment
Patients received bendamustine at a dose of 120 mg/m2 infused over 60 min on days 1 and 2 
of each 21-day cycle along with rituximab 375 mg/m2 after bendamustine on day 1 of each 
cycle. Patients with ECOG PS of 3 at baseline were allowed to receive bendamustine at a 
dose of 90 mg/m2 daily, with a dose increase to 120 mg/m2 daily if their ECOG PS 
improved to ≤ 2 after 3 cycles of BR. Pre-phase steroid therapy with prednisone 100 mg/day 
for five days was permitted prior to the initiation of BR in patients with poor functional 
status at the initial presentation (Pfreundschuh, et al 2004). Primary prophylaxis with 
granulocyte colony-stimulating factor (pegfilgastrim or filgastrim) was administered as part 
of the protocol.
National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 
4.0 (http://evs.nci.nih.gov/ftp1/CTCAE/
CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf), were used to assess toxicity. If 
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patients developed grade 4 haematological or grade 3 or higher non-haematological 
toxicities, the cycle was prolonged to 28 days. If further toxicity occurred at the reduced 
dose level, the bendamustine dose was reduced to 90 mg/m2 in patients who were receiving 
120 mg/m2. For patients who were already at 90 mg/m2 when further toxicity occurred, 
study treatment was discontinued. Toxicities must have resolved to grade 2 or lower before 
beginning the next cycle. Treatment was postponed if ANC had not recovered to at least 1.0 
× 109/l and platelets to at least 75 × 109/l by the time of the next cycle. If therapy was held 
for 14 or more days, the protocol directed treatment was discontinued.
Patients were treated for up to 8 cycles and patients were assessed for response after 3 
cycles. If they had CR, they were treated for 3 additional cycles. If they failed to achieve a 
partial response (PR), they were removed from the protocol. If they achieved PR, they were 
treated for 3–5 additional cycles. Treatment was discontinued in patients with disease 
progression, concomitant illness preventing further treatment administration, unacceptable 
adverse events, or at the discretion of the patient or investigator.
Patients were also asked to complete a geriatric assessment using the tool developed by 
Hurria et al (2005) at baseline. The geriatric assessment consists of both an external 
evaluation completed with the assistance of research associates and a patient questionnaire. 
The external evaluation consists of the Blessed Orientation-Memory-Concentration (BOMC) 
test (Katzman, et al 1983, Kawas, et al 1995), which includes questions to screen for 
macroscopic cognitive impairment, the Karnofsky Performance Status tool (KPS) and the 
Timed Up and Go (TUG) test (Podsiadlo and Richardson 1991, Shumway-Cook, et al 2000). 
Patients completed a questionnaire which includes assessments designed to evaluate 
functional status including the Instrumental Activities of Daily Living (IADL), a subscale of 
the Multidimensional Functional Assessment Questionnaire (MFAQ): Older American 
Resources and Services (OARS) (Fillenbaum and Smyer 1981), and the Activities of Daily 
Living (ADL) subscale of the Medical Outcomes Study (MOS) Physical Health. The patient 
questionnaire also includes a self-reporting version of the KPS as well as a question asking 
patients to report the number of times they have fallen in the last 6 months (Teno, et al 
1990), a co-morbidity scale (the Physical Health Section of the OARS) (Extermann, et al 
1998), a request for patients to list all current medications they are taking (Lees and Chan 
2011), an assessment of psychological distress and well-being (Kelly, et al 2008, Rumpf, et 
al 2001, Trainor, et al 2013), and evaluations of social functioning and social support 
(Sherbourne 1991).
Patients were evaluated every 6 months for 3 years after completion of treatment or until 
death. Patients removed from the study for adverse events were followed until resolution or 
stabilization of the adverse event and then subsequently for 3 years after discontinuation of 
treatment or until death.
Assessment of Efficacy
The primary endpoint for the trial was the rate of CR. Response rates were evaluated as 
defined by the International Harmonization Project for Response Criteria (Cheson, et al 
2007). DFS was measured from the time of occurrence of disease-free state or attainment of 
CR to disease recurrence or death as a result of lymphoma or acute toxicity of treatment. 
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PFS was defined as the time from the start of treatment until lymphoma progression or death 
as a result of any cause. OS was defined as the time from start of treatment until death as a 
result of any cause.
Statistical Methods
Sample size was determined using historical data and the null hypothesis that the CR rate is 
50% or less tested against a one-sided alternative. The trial used a Simon-like two-stage 
design with relaxed stopping for futility (Ivanova and Deal 2016) using CR for primary 
analysis and both PR and CR for futility analysis. A total sample size of 37 would be 
required to achieve 80% power if the true CR rate was 70% with plan to reject the null 
hypothesis if 24 or more patients responded out of 37. If the number of CRs plus PRs in the 
first 23 patients was less than 13, the trial would be stopped for futility. The type I error rate 
is at most 0.05, assuming a CR rate of 50% and a PR rate of at most 20%. There was a 
mandatory interim analysis for futility after enrolment of the first 23 patients.
An intention to treat approach was followed in all data summaries and analyses. The CR and 
ORR rates were estimated and 95% confidence interval (CI) computed. PFS and OS were 
summarized using the Kaplan-Meier method. All demographic and analytic data were 
summarized by descriptive statistics. P-values < 0.05 were considered statistically 
significant. Patients who were enrolled in the study but who voluntarily withdrew prior to 
treatment or never initiated treatment due to the development of inter-current illness or death 
were not included in the analysis.
Results
Patients
Patient characteristics are summarized in Table I. Twenty-eight patients were assessed for 
eligibility; 4 patients were excluded for not meeting the inclusion criteria and 1 patient 
eventually declined to participate. Twenty-three patients were enrolled between March 2011 
and May 2013 with the majority (82%) having stage III or IV disease at baseline. The 
median age was 80 years (range 65–89) and 79% of patients had IPI score of ≥ 3. More than 
half the patients (52%) presented with poor functional status with ECOG score of ≥ 2 prior 
to therapy, including 6 patients with ECOG score of 3. DLBCL subtype was determined by 
immunohistochemistry with 7 patients with germinal centre B-cell like (GCB) subtype, 12 
patients with non-GCB subtype and 4 patients not able to be classified(Hans, et al 2004). 
MYC, BCL2, and BCL6 status by fluorescence in situ hybridization (FISH) or 
immunohistochemistry analyses were not available at the time of enrolment in the majority 
of patients. Although patients with transformed lymphoma were not excluded from this 
study, there was only one patient enrolled in the trial with a history of previously untreated 
follicular lymphoma. Baseline geriatric assessment characteristics of the patients are listed 
in Supplementary Table 1. Of note, 4 of 18 patients (22%) experienced 2 or more falls in the 
past 6 months, 12 of 18 patients (67%) had impairments in their IADL, and 11 of 18 patients 
(61%) had a TUG score of 14 s or more or were unable to do the test.
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The median number of cycles completed per patient was 6. Three out of 23 patients received 
an initial dose of 90 mg/m2. Out of 23 patients included in the study, 11 patients completed 
treatment per protocol, 3 patients discontinued therapy secondary to adverse events, 2 
patients died while receiving therapy, 2 patients withdrew from the study, 2 patients 
discontinued therapy because of disease progression while receiving treatment, 1 patient 
discontinued therapy because of clinical deterioration, 1 patient discontinued therapy due to 
other complicating disease (stroke) and 1 patient withdrew due to physician preference. This 
study represents the data after inclusion of the first 23 patients at the planned interim 
analysis. The data analysis was performed prior to the previously determined 3-year follow-
up period because the study did not reach the initially planned sample size to determine the 
survival rates in a statistically significant manner as secondary objectives.
Safety/Toxicity
The major grade 3 or higher adverse events were haematological toxicities and are 
summarized in Table II. Common non-haematological toxicities included fatigue (70%), 
anorexia (52%), nausea (39%), hypoalbuminemia (30%), elevated AST (30%) and elevated 
alkaline phosphatase (30%) and were mostly grade 1 or 2. Three patients discontinued 
treatment because of adverse events: 1 patient had prolonged thrombocytopenia, 1 patient 
had weakness and failure to thrive and 1 patient had persistent grade 3 toxicities including 
infections and an overall failure to thrive.
Sixteen out of 23 patients died during the study period (Table III). Four deaths were felt to 
be treatment-related, five deaths were felt to be disease-related and seven deaths were 
secondary to other causes not considered by the investigators to be related to study treatment 
(see Table III for more details).
Efficacy/Response
The ORR was 78%, with 12 CRs (52%, 95% CI: 30.6%–73.2%) and six partial responses 
(26%, 95% CI: 10.2%–48.4%). One patient had stable disease. Progressive disease was 
documented in one patient and three patients were not evaluable for disease progression due 
to early deaths.
At the median follow-up of 29 months, the median OS was 10.2 months (95% CI, 3.8–13.3 
months) and the median PFS was 5.4 months (95% CI, 3.8–10.2 months) (Figure 1). For 
patients with ECOG score ≥ 2, the median OS was 3.7 months compared to median OS of 
10.4 months for patients with ECOG score 0–1, although this difference was not statistically 
significant (p=0.17). There was no significant difference in OS between patients aged 80 
years and older and patients younger than 80 years (6.4 months vs 10.2 months, respectively, 
p = 0.43). There were also some sustained responses seen in patients, with 6 out of 7 patients 
who were alive at last evaluation without evidence of disease progression. The maximum 
PFS was 41.9 months and 3 other patients had PFS over 2 years at the time of data cut-off.
The only baseline geriatric assessment measure associated with OS and PFS was number of 
falls. Four out of 18 patients who had 2 or more falls in the 6 months prior to initiation had a 
median OS of 4.0 months compared to a median OS of 10.7 months in the 14 patients with 0 
or 1 fall (p= 0.001) (Figure 2).
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Four out of 9 evaluable patients (44%) with non-GCB subtype and 5 out of 7 (71%) patients 
with GCB subtype had CR, but this difference was not statistically significant (p=0.36). 
There was no significant difference in OS based on pathology subtype with mean OS of 10.5 
months (95% CI: 2.6-NR) in non-GCB subtype and 9.9 months (95% CI: 2.7-NR) in GCB 
subtype.
Discussion
This study aimed to find a tolerable and efficacious treatment for elderly, frail patients with 
DLBCL.
There have been a few phase II trials investigating the safety and efficacy of BR in patients 
with relapsed and refractory DLBCL which showed overall good response and tolerance, 
with one study showing an ORR of 45.8% (Vacirca, et al 2014) and the other study showing 
an ORR of 62.7% (Ohmachi, et al 2013). The most frequently observed grade 3 or 4 
toxicities in both studies were haematological with the non-haematological toxicities being 
mostly grade 1 or 2 in severity. Given the promising results and safety profile of BR in the 
relapsed/refractory setting, we proposed a phase II trial of BR in elderly patients with 
DLBCL in the first line setting. We used a dosing regimen of 120 mg/m2 of bendamustine 
and a 21-day cycle to maximize response rates based on the data by Ohmachi et al (2013), 
which showed promising efficacy and tolerability in patients with relapsed/refractory 
DLBCL.
This is the first prospective trial investigating the safety and efficacy of BR specifically in 
patients with previously untreated DLBCL. Although the response rates were high with 
ORR greater than 75% and a CR rate of 52%, OS rates were low with a median of less than 
one year in the current study.
The results of our study are comparable to recently published retrospective studies of BR in 
the elderly. The safety and efficacy of BR was retrospectively assessed in 20 consecutive 
patients with aggressive lymphoma in the first line or relapsed/refractory setting (Horn, et al 
2012). The ORR was 55% with a median PFS and OS of 8.3 and 19.4 months, respectively. 
This was a younger population than that of our study with a median age of 72 years. In 
addition, patients in this study received a lower dose of bendamustine, 90 mg/m2 in a 28-day 
cycle. In another retrospective analysis, 13 patients with DLBCL who received BR as first 
line therapy were evaluated for response, with an ORR of 62% and median PFS and OS of 6 
and 9 months, respectively (Walter, et al 2012). There has been one other phase II trial 
investigating the safety and efficacy of BR in the first line setting, but this trial included 
patients with several different types of aggressive B-cell lymphoma, as opposed to DLBCL 
alone (Weidmann, et al 2011). This trial enrolled 14 patients who were aged 80 years or 
older (median age of 85 years) with aggressive B-cell lymphomas who did not qualify for 
treatment with R-CHOP. The CR rate was 54% with a 15% PR rate and median OS and PFS 
of 7.7 months.
The toxicity profile of the BR combination in our study was similar to that seen in other 
investigations of this regimen, with haematological toxicities being the most common 
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adverse events. There were, however, four deaths that were felt to be treatment-related and 
an overall high number of deaths with 16 patients dying during the evaluation period. At the 
time of the mandatory interim analysis for futility, the one-year PFS was 26% with 95% CI 
of 13% to 52%. Because this PFS rate was predictive of lower than a 2 or 3 year-PFS of 
around 50% or higher seen in historical controls of elderly with DLBCL treated with other 
regimens (Alvarez, et al 2014, Hainsworth, et al 2010, Jung, et al 2015, Kasahara, et al 2011, 
Kreher, et al 2014, Meguro, et al 2012, Peyrade, et al 2011), the decision was made to 
terminate the trial at the time of interim analysis. The lower survival rates in our study are 
probably related to the fact that the population in the present trial was more “unfit” and frail 
than the other populations studied with the presence of a high IPI, an average age of 80 
years, and more than half of the patients having a performance status of 2 or 3. In addition, a 
large proportion of our patients had significant impairments, as demonstrated by their 
baseline geriatric assessment (Table S1). These patients had significant comorbidities at 
baseline, which explains the higher number of unrelated deaths during or after therapy. 
However, it is important to note that this population may be more representative of the older 
and frail population commonly seen in clinical practice. In addition, as part of the University 
of North Carolina Cancer Network, this study was able to recruit patients from a variety of 
practice settings across the state, which also suggests that the patients in this study may be a 
more accurate representation of patients seen in the actual clinical setting.
There have been several studies investigating dose variations of R-CHOP in elderly or frail 
patients as an alternative therapy for DLBCL. A phase 2 study of rituximab combined with 
low-dose CHOP (R-mini-CHOP) in patients greater than 80 years old had a median OS of 
29 months, which, is more favourable than that seen in this study (Peyrade, et al 2011). The 
median age of 83 years in the R-mini-CHOP study is comparable to that in the present study, 
but it included a much more “fit” elderly population with the majority of patients having an 
ECOG PS of 0 and 1 and no significant comorbidities, including contraindication to 
receiving doxorubicin. The results of a retrospective study of patients with newly diagnosed 
DLBCL who were felt to be unfit to receive R-CHOP and instead received either R-mini-
CHOP or BR showed a more limited survival (Hammersen, et al 2014). The ORR for BR 
was 64% with a median PFS and OS of 6 and 15 months, respectively. The results for R-
mini-CHOP in the same study were comparable to the BR group with an ORR of 60% and 
median PFS and OS of 6 and 8 months, respectively. These patients had a median age 
greater than 80 years and were less “fit” than those in the other studies discussed, with about 
one third of patients having an ECOG score of 2 or greater. The results of the above studies 
suggest that dose variations of R-CHOP may be a feasible alternative regimen in carefully 
selected elderly patients with a good performance status. Whether the results with such an 
approach would be an improvement over those described in this report with BR is unknown.
Lastly, a geriatric assessment was utilized in this study, and a recent history of a fall was 
predictive of worse survival in a statistically significant manner. Obtaining a history of falls 
is a relatively simple intervention and it may serve as a strong predictive measure of 
outcome when considering any potentially morbid chemotherapy regimen in elderly patients 
with DLBCL. This study was limited by a small sample size because it was terminated 
prematurely at the time of interim analysis. In addition, more complete post-treatment 
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geriatric assessment data at the time of follow-up would have strengthened the geriatric 
assessment analysis.
In summary, combination therapy with BR demonstrated high response rates in the first-line 
setting in an elderly population with DLBCL who were deemed poor candidates for R-
CHOP therapy, but survival rates were still low. Therefore, BR, especially with high dose 
bendamustine, should be used with caution in future clinical trials involving older patients 
with DLBCL with poor functional status. Nevertheless, high response rates and sustained 
responses in some of the responders are encouraging, and use of this regimen with lower 
doses of drugs, fewer cycles of therapy, or in combination with a novel agent may be worth 
consideration in this less robust population. Notably, patients enrolled in this trial were more 
representative of the actual clinical setting, which makes this study highly relevant for 
clinical practice. There is currently no standard of care in the treatment of elderly and less fit 
patients with DLBCL, and more clinical trials of alternative therapies are urgently needed to 
improve survival outcomes in this patient population.
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Figure 1. 
Kaplan-Meier estimates of median overall survival (OS) and progression-free survival 
(PFS). The median OS was 10.2 months (95% confidence interval [CI]: 3.8–13.3). The 
median PFS was 5.4 months (95% CI: 3.8, 10.2).
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Figure 2. 
Kaplan-Meier estimates of median overall survival (OS) based on number of falls. The 
median OS was 4.0 months (95% confidence interval [CI]: 0.77, 6.8) for patients with 2 or 
more falls and 10.7 months (95% CI: 6.0, not reached) for patients with 0 or 1 falls.
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Table I
Patient Characteristics (N=23)
Variable N (%)
Age, years (median, range) 80 (65–89)
Gender
 Male 12 (52%)
 Female 11 (48%)
Race
 White 21 (91%)
 Other 2 (9%)
Stage
 II 4 (17%)
 III 7 (30%)
 IV 12 (52%)
ECOG Performance Status
 0 2 (9%)
 1 9 (39%)
 2 6 (26%)
 3 6 (26%)
International Prognostic Index
 2 5 (22%)
 3 5 (22%)
 4 8 (35%)
 5 5 (22%)
Lactate dehydrogenase
 Normal 8 (35%)
 Elevated 15 (65%)
Pathology Subtype
 Non-Germinal Centre 12 (52%)
 Germinal Centre 7 (30%)
 Not classified 4 (17%)
ECOG, Eastern Cooperative Oncology Group
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Table II
Toxicity
TOXICITY Number of Patients with 
Grade 3
Number of Patients with 
Grade ≥ 4
Percentage of all patients with 
grade ≥ 3
Haematological Toxicities
 Lymphopenia 8 8 70%
 Anaemia 6 0 26%
 Neutropenia 1 3 17%
 Thrombocytopenia 1 3 17%
 Lymphocytosis 1 0 4%
Non-Haematological Toxicities
 Fatigue 3 0 13%
 Anorexia 0 2 9%
 Hyperglycaemia 2 0 9%
 Urinary tract infection 2 0 9%
 Arthralgia 1 0 4%
 Atrial fibrillation 1 0 4%
 Cognitive disturbance 1 0 4%
 Generalized muscle weakness 1 0 4%
 Heart failure 0 1 4%
 Hypoalbuminaemia 1 0 4%
 Hyponatraemia 1 0 4%
 Infusion related reaction 1 0 4%
 Myalgia 1 0 4%
 Nausea 1 0 4%
 Pleural effusion 1 0 4%
 Maculopapular rash 1 0 4%
 Sepsis 0 1 4%
 Skin infection 1 0 4%
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Table III
Cause of Death.
Age (years) Sex Response Cycles completed (n) Description
Treatment-Related
81 F PR 3 Anorexia1
69 M NE 3 Pneumonia
78 F PR 6 Pneumonia
79 F CR 5 Anorexia1
Disease-Related
78 M PR 5 Disease progression after 5 cycles
85 F PD 2 Disease progression after 2 cycles
72 M PR 6 Disease progression after 6 cycles
83 F CR 6 Disease progression after 6 cycles
84 M CR 6 Disease progression after 6 cycles
Non-Treatment or Disease Related
73 M CR 6 Acute cerebral vascular accident after completion of therapy
86 F SD 2 Congestive heart failure with underlying heart disease
87 F CR 4 Femoral neck fracture
88 M NE 1 Treatment stopped after cerebral vascular accident
87 M CR 3 Unknown. Patient withdrew from the study
85 M NE 2 Unknown. Sudden death at home
65 F CR 6 Respiratory failure secondary to pneumonia after treatment completed
M= male, F= female, CR = Complete response, PR = Partial response, SD = stable disease, PD = progressive disease, NE = not evaluable
1A potential causal relationship was determined between treatment and anorexia, although this was not definitive.
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